Publications by Medical Specialty - Cardiology
These publications were authored or co-authored by Quest Diagnostics staff.
- Clinical and Lab healthcare professionals
- Endocrinology, Diabetes & Metabolism
- Family medicine practitioners
- General Health and Wellness
- Geriatrics/Age Management
- Health Information Technology
- Infectious Disease
- Internal Medicine
- Nurse practitioners
- Pathology, Anatomic
- Pathology, Laboratory Medicine
- Physician assistants
- Prescription Drug Monitoring
- Sports Medicine
- Toxicology/Pain Management
- Women's Health/OB/GYN
Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study.
Quest Diagnostics Authors: Caulfield, MP
Authors: Landenhed M, Engstrom G, Gottsater A, Hedblad B, Newton-Cheh C, Melander O, Smith JG
J Am Heart Assoc 2015;4:e001513
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.
Quest Diagnostics Authors: Devlin, J
Authors: Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS
Quest Diagnostics Authors: Kroll, MH
Authors: Srisawasdi P, Vanavanan S, Rochanawutanon M, Kruthkul K, Kotani K
Clin Biochem 2015;48:495-502
Low-Density Lipoprotein Particle Number Is Associated With Cardiovascular Events Among Those Not Classified Into Statin Benefit Groups.
Authors: Melander O, Shiffman D, Caulfield MP, Louie JZ, Rowland CM, Devlin JJ, Krauss RM.
J Am Coll Cardiol. 2015;65:2571-3.
Authors: Ponda MP, Huang X, Odeh MA, Breslow JL, Kaufman HW.
Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy.
Authors: Shiffman D, Trompet S, Louie JZ, Rowland CM, Catanese JJ, Iakoubova OA, Kirchgessner TG, Westendorp RG, de Craen AJ, Slagboom PE, Buckley BM, Stott DJ, Sattar N, Devlin JJ, Packard CJ, Ford I, Sacks FM, Jukema JW.
PLoS One. 2012;7:e38240.
Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
Authors: Shiffman D, Slawsky K, Fusfeld L, Devlin JJ, Goss TF.
Clin Ther. 2012;34:1387-1394.
Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients.
Authors: Noori N, Caulfield MP, Salameh WA, Reitz RE, Nicholas SB, Molnar MZ, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K.
Clin J Am Soc Nephrol. 2011;6:2861-2870.